Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Vibrant festival highlights cultural charm of various Chinese ethnic groupsCher, Ozzy Osbourne among 2024 Rock & Roll Hall of Fame inducteesREVEALED: Former Tory minister who leapt to Angela Rayner's defence... is working for LabourFive rockets are fired from Iraq towards US military base in SyriaCher, Ozzy Osbourne among 2024 Rock & Roll Hall of Fame inducteesDirect flights resume between Chengdu, AucklandHorrifying moment caregiver, 26, smacks 93Five rockets are fired from Iraq towards US military base in SyriaLos Angeles sheriff's deputy dies months after being injured in fire inside mobile gun rangeUS and Philippine forces launch combat drills in the disputed South China Sea